Scott & Selber Inc. Purchases 37 Shares of Thermo Fisher Scientific Inc. $TMO

Scott & Selber Inc. lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.6% during the second quarter, HoldingsChannel reports. The firm owned 6,209 shares of the medical research company’s stock after buying an additional 37 shares during the quarter. Scott & Selber Inc.’s holdings in Thermo Fisher Scientific were worth $2,518,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Brighton Jones LLC increased its holdings in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after acquiring an additional 988 shares in the last quarter. Revolve Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares in the last quarter. Fifth Third Wealth Advisors LLC raised its holdings in Thermo Fisher Scientific by 1.0% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 7,037 shares of the medical research company’s stock worth $3,502,000 after buying an additional 73 shares during the period. Mirador Capital Partners LP lifted its position in Thermo Fisher Scientific by 3.3% in the 1st quarter. Mirador Capital Partners LP now owns 8,829 shares of the medical research company’s stock valued at $4,393,000 after acquiring an additional 280 shares in the last quarter. Finally, Czech National Bank raised its stake in shares of Thermo Fisher Scientific by 5.9% in the 1st quarter. Czech National Bank now owns 87,854 shares of the medical research company’s stock valued at $43,716,000 after purchasing an additional 4,920 shares during the period. Institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Up 1.1%

Shares of TMO stock opened at $464.18 on Monday. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $623.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The stock has a market cap of $175.28 billion, a price-to-earnings ratio of 26.85, a PEG ratio of 2.52 and a beta of 0.75. The firm’s 50-day moving average is $476.70 and its 200-day moving average is $447.15.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the prior year, the company earned $5.37 earnings per share. The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 9.95%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TMO. Raymond James Financial reaffirmed an “outperform” rating and set a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Evercore ISI decreased their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research note on Tuesday, July 8th. Wells Fargo & Company cut their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a research report on Thursday, July 24th. HSBC reaffirmed a “hold” rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Robert W. Baird increased their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a research note on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $588.35.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.